JP2018518974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518974A5 JP2018518974A5 JP2017567178A JP2017567178A JP2018518974A5 JP 2018518974 A5 JP2018518974 A5 JP 2018518974A5 JP 2017567178 A JP2017567178 A JP 2017567178A JP 2017567178 A JP2017567178 A JP 2017567178A JP 2018518974 A5 JP2018518974 A5 JP 2018518974A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antigen recognition
- receptor
- cells
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 32
- 102000038129 antigens Human genes 0.000 claims 32
- 108091007172 antigens Proteins 0.000 claims 32
- 102100008794 TNFRSF17 Human genes 0.000 claims 21
- 210000004027 cells Anatomy 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 19
- 101710030909 TNFRSF13B Proteins 0.000 claims 17
- 102100009744 TNFRSF13B Human genes 0.000 claims 17
- -1 LeY Proteins 0.000 claims 15
- 101710038604 TNFRSF17 Proteins 0.000 claims 14
- 102100005826 CD19 Human genes 0.000 claims 13
- 101700087100 CD19 Proteins 0.000 claims 13
- 102100000189 CD22 Human genes 0.000 claims 13
- 101700020617 CD22 Proteins 0.000 claims 13
- 102100003279 CD38 Human genes 0.000 claims 12
- 101700044948 CD38 Proteins 0.000 claims 12
- 102000018109 Glypican-3 Human genes 0.000 claims 12
- 108050007237 Glypican-3 Proteins 0.000 claims 12
- 102100010587 SDC1 Human genes 0.000 claims 12
- 101700070405 SDC1 Proteins 0.000 claims 12
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 12
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 12
- 230000000139 costimulatory Effects 0.000 claims 12
- 102100016493 CD33 Human genes 0.000 claims 11
- 101700017647 CD33 Proteins 0.000 claims 11
- 102100018760 IL3RA Human genes 0.000 claims 11
- 101700029869 IL3RA Proteins 0.000 claims 11
- 102100005828 CD5 Human genes 0.000 claims 10
- 101700066525 CD5 Proteins 0.000 claims 10
- 101710030372 CLSTN1 Proteins 0.000 claims 10
- 101710038812 CS1 Proteins 0.000 claims 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 10
- 101710021997 ITPRID2 Proteins 0.000 claims 10
- 102100000165 MS4A1 Human genes 0.000 claims 10
- 101710010909 MS4A1 Proteins 0.000 claims 10
- 102100017640 SLAMF7 Human genes 0.000 claims 10
- 101710030435 SLAMF7 Proteins 0.000 claims 10
- 101700036918 XMT1 Proteins 0.000 claims 10
- 101710029131 rpsA Proteins 0.000 claims 10
- 101710041788 ygbT Proteins 0.000 claims 10
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-N-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-N,1-N-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 7
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 7
- 108060000228 ADRM1 Proteins 0.000 claims 6
- 102100016549 ANPEP Human genes 0.000 claims 6
- 101710028178 ANPEP Proteins 0.000 claims 6
- 101700027514 CD14 Proteins 0.000 claims 6
- 102100003268 CD14 Human genes 0.000 claims 6
- 102100005833 CD68 Human genes 0.000 claims 6
- 102100001891 CTAG1A Human genes 0.000 claims 6
- 101710004449 CTAG1A Proteins 0.000 claims 6
- 102100015540 FCGR1A Human genes 0.000 claims 6
- 101710003440 FCGR1A Proteins 0.000 claims 6
- 101710009074 FLT3 Proteins 0.000 claims 6
- 102100019327 FUT4 Human genes 0.000 claims 6
- 101700004786 FUT4 Proteins 0.000 claims 6
- 102100008185 IL6R Human genes 0.000 claims 6
- 101710044247 ITGA2B Proteins 0.000 claims 6
- 102100019332 ITGA2B Human genes 0.000 claims 6
- 102100001477 ITGB3 Human genes 0.000 claims 6
- 101710006664 ITGB3 Proteins 0.000 claims 6
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 6
- 102100016985 KIT Human genes 0.000 claims 6
- 101710009391 KIT Proteins 0.000 claims 6
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 6
- 101710030862 TNFRSF13C Proteins 0.000 claims 6
- 102100009743 TNFRSF13C Human genes 0.000 claims 6
- 230000011664 signaling Effects 0.000 claims 6
- 102100013077 CD4 Human genes 0.000 claims 5
- 101700022938 CD4 Proteins 0.000 claims 5
- 102100008191 CD8A Human genes 0.000 claims 5
- 101700054655 CD8A Proteins 0.000 claims 5
- 108091006028 chimera Proteins 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102100007290 CD274 Human genes 0.000 claims 3
- 101710012053 CD274 Proteins 0.000 claims 3
- 102100019283 CD52 Human genes 0.000 claims 3
- 108010065524 CD52 Antigen Proteins 0.000 claims 3
- 102100005175 CSF1R Human genes 0.000 claims 3
- 101700063802 CSF1R Proteins 0.000 claims 3
- 101710004393 HAVCR2 Proteins 0.000 claims 3
- 102100016384 HAVCR2 Human genes 0.000 claims 3
- 102100004550 IL15RA Human genes 0.000 claims 3
- 101710035264 IL15RA Proteins 0.000 claims 3
- 108010065805 Interleukin-12 Proteins 0.000 claims 3
- 108090000172 Interleukin-15 Proteins 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 108010002586 Interleukin-7 Proteins 0.000 claims 3
- 102100013504 RPL17 Human genes 0.000 claims 3
- 108060007796 SPATA2 Proteins 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 230000002708 enhancing Effects 0.000 claims 3
- 108010074108 interleukin-21 Proteins 0.000 claims 3
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 102100019461 CD28 Human genes 0.000 claims 2
- 101700033362 CD28 Proteins 0.000 claims 2
- 102100019453 CD7 Human genes 0.000 claims 2
- 101700063101 CD7 Proteins 0.000 claims 2
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims 2
- 210000000581 Natural Killer T-Cells Anatomy 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 201000009251 multiple myeloma Diseases 0.000 claims 2
- 230000002062 proliferating Effects 0.000 claims 2
- 206010002022 Amyloidosis Diseases 0.000 claims 1
- 206010002023 Amyloidosis Diseases 0.000 claims 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims 1
- 208000001715 Osteoblastoma Diseases 0.000 claims 1
- 101700059076 PTPRC Proteins 0.000 claims 1
- 102100005499 PTPRC Human genes 0.000 claims 1
- 208000003359 Plasma Cell Leukemia Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000008064 heavy chain disease Diseases 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Claims (20)
- 以下を含む操作された細胞
(i.) 第1の抗原認識ドメイン、第1のシグナルペプチド、第1のヒンジ領域、第1の膜貫通ドメイン、第1の共刺激ドメイン、および第1のシグナル伝達ドメインを含む第1のキメラ抗原レセプターポリペプチド、そして
(ii.) 第2の抗原認識ドメイン、第2のシグナルペプチド、第2のヒンジ領域、第2の膜貫通ドメイン、第2の共刺激ドメイン、および第2のシグナル伝達ドメインを含む第2のキメラ抗原受容体ポリペプチドを有する、ここにおいて第1の抗原認識ドメインは第2の抗原認識ドメインとは異なる。 - ここにおける第1のキメラ抗原レセプターポリペプチドおよび第2のキメラエンジニアリングポリペプチドは、単一のポリペプチド分子上にある、そしてまた、ここで、高い効率の切断部位を含むアミノ酸配列は、第1のキメラ抗原レセプターポリペプチドと第2のキメラ抗原レセプターポリペプチドとの間に配置される、請求項１に記載の操作された細胞。
- 高効率切断部位が、P2A、T2A、E2A、およびF2Aからなるグループから選択される請求項２に記載の操作された細胞。
- 第1の共刺激ドメインおよび第2の共刺激ドメインは異なる、請求項１に記載の操作された細胞。
- 第1の共刺激ドメインはCD28を含み、第2の共刺激ドメインは4-1BBを含む、請求項１に記載の操作された細胞。
- 第1の抗原認識ドメインの標的は、インターロイキン6受容体、NY-ESO-1、アルファフェトプロテイン（AFP）、グリピカン-3（GPC3）、BAFF-R、BCMA、TACI、LeY、CD5、CD13、CD14、CD15、CD19、CD20、CD22、CD33、CD41、CD61、CD64、CD68、CD117、CD123、CD138、CD267、CD269、CD38、Flt3受容体そしてCS1からなるグループから選ばれ、第2の抗原認識ドメインの標的はインターロイキン6受容体、NY-ESO-1、アルファフェトプロテイン（AFP）、グリピカン-3（GPC3）、BAFF-R、BCMA、TACI、LeY、CD5、CD13、CD14、CD15、CD19、CD20、CD22、CD33、CD41、CD61、CD64、CD68、CD117、CD123、CD138、CD267、CD269、CD38、Flt3受容体そしてCS1からなるグループより選ばれる、請求項１に記載された操作された細胞。
- 操作された細胞はT細胞、CD4 T細胞、CD8 T細胞、ナチュラルキラー細胞、NKT細胞またはNK-92細胞である、請求項１に記載された操作された細胞。
- CD2、CD3、CD4、CD5、CD7、CD8、CD45、CD52、CD19、CD20、CD22、CD33、CD38、CD123、CD138、CD267、CD269、CD38、およびCS1抗原認識ドメインを含むキメラ抗原レセプターポリペプチドならびに場合によりPD-1、PD-L1、CSF1R、CTAL-4、TIM-3、TGFRベータ、IL-2、IL-7、IL-12、IL-15、IL-15RA、IL-21、それらの機能的フラグメント、またはそれらの組み合わせを含むエンハンサーを含むポリペプチドを含む操作された細胞。
- 機能的断片がsushiドメインを含む、請求項８に記載の操作された細胞。
- 細胞増殖性疾患を治療する方法であって、
ａ．（ｉ）第1の抗原認識ドメイン、第1のシグナルペプチド、第1のヒンジ領域、第1の膜貫通ドメイン、第1の共刺激ドメイン、および第1のシグナル伝達ドメインを含む第1のキメラ抗原レセプターポリペプチド、ならびに
（ｉｉ）第2の抗原認識ドメイン、第2のシグナルペプチド、第2のヒンジ領域、第2の膜貫通ドメイン、第2の共刺激ドメイン、および第2のシグナル伝達ドメインを含む第2のキメラ抗原レセプターポリペプチド
を含む治療上有効量の操作された細胞を、それを必要とする患者に投与する工程であって、
第1の抗原認識ドメインは、第2の抗原認識ドメインとは異なり、
第1のキメラ抗原レセプターポリペプチドは、インターロイキン6受容体、NY-ESO-1、アルファフェトプロテイン（AFP）、グリピカン-3（GPC3）、BAFF-R、BCMA、TACI、LeY、CD5、CD13、CD14、CD15、CD19、CD20、CD22、CD33、CD41、CD61、CD64、CD68、CD117、CD123、CD138、CD267、CD269、CD38、Flt3受容体またはCS1を含み、
第2のキメラ抗原レセプターポリペプチドは、インターロイキン6受容体、NY-ESO-1、アルファフェトプロテイン（AFP）、グリピカン-3（GPC3）、BAFF-R、BCMA、TACI、LeY、CD5、CD13、CD14、CD15、CD19、CD20、CD22、CD33、CD41、CD61、CD64、CD68、CD117、CD123、CD138、CD267、CD269、CD38、Flt3受容体またはCS1を含む工程、あるいは、
CD2、CD3、CD4、CD5、CD7、CD8、CD45、CD52、CD19、CD20、CD22、CD33、CD38、CD123、CD138、CD267、CD269、CD38、およびCS1抗原認識ドメインを含むキメラ抗原レセプターポリペプチドならびに場合によりPD-1、PD-L1、CSF1R、CTAL-4、TIM-3、TGFRベータ、IL-2、IL-7、IL-12、IL-15、IL-15RA、IL-21、それらの機能的フラグメント、またはそれらの組み合わせを含むエンハンサーを含む改変ポリペプチドを含む治療上有効量の操作された細胞を、それを必要とする患者に投与する工程
を含む方法。 - 細胞増殖性疾患が、形質細胞白血病、多発性骨髄腫、形質細胞腫、アミロイドーシス、waldestromのマクログロブリン腫、重鎖疾患、孤立性骨芽細胞腫、不確定性のモノクローナル性ガンマパシー（MGUS）、または多発性骨髄腫のくすぶりを含む、請求項１０に記載の方法。
- 細胞が、CD2、CD3、CD4、CD5、CD7、CD8、CD45、CD52、CD19、CD20、CD22、CD33、CD38、CD123、CD138、CD267、CD269、CD38、およびCS1抗原認識ドメインを含むキメラ抗原レセプターポリペプチドならびに場合によりPD-1、PD-L1、CSF1R、CTAL-4、TIM-3、TGFRベータ、IL-2、IL-7、IL-12、IL-15、IL-15RA、IL-21、それらの機能的フラグメント、またはそれらの組み合わせを含むエンハンサーを含む改変ポリペプチドを含まない、請求項１０に記載の方法。
- 細胞が、
（ｉ）第1の抗原認識ドメイン、第1のシグナルペプチド、第1のヒンジ領域、第1の膜貫通ドメイン、第1の共刺激ドメイン、および第1のシグナル伝達ドメインを含む第1のキメラ抗原レセプターポリペプチド、ならびに
（ｉｉ）第2の抗原認識ドメイン、第2のシグナルペプチド、第2のヒンジ領域、第2の膜貫通ドメイン、第2の共刺激ドメイン、および第2のシグナル伝達ドメインを含む第2のキメラ抗原レセプターポリペプチド
を含まず、
第1の抗原認識ドメインは、第2の抗原認識ドメインとは異なり、
第1のキメラ抗原レセプターポリペプチドは、インターロイキン6受容体、NY-ESO-1、アルファフェトプロテイン（AFP）、グリピカン-3（GPC3）、BAFF-R、BCMA、TACI、LeY、CD5、CD13、CD14、CD15、CD19、CD20、CD22、CD33、CD41、CD61、CD64、CD68、CD117、CD123、CD138、CD267、CD269、CD38、Flt3受容体またはCS1を含み、
第2のキメラ抗原レセプターポリペプチドは、インターロイキン6受容体、NY-ESO-1、アルファフェトプロテイン（AFP）、グリピカン-3（GPC3）、BAFF-R、BCMA、TACI、LeY、CD5、CD13、CD14、CD15、CD19、CD20、CD22、CD33、CD41、CD61、CD64、CD68、CD117、CD123、CD138、CD267、CD269、CD38、Flt3受容体またはCS1を含む、
請求項１０に記載の方法。 - 第1の抗原認識ドメインは、CD267またはCD269を含み、第2の抗原認識ドメインは、CD19、CD38、CD138、CD138またはCD1を含む、請求項１２に記載の方法。
- 第1の抗原認識ドメインは、CD19を含み、第2の抗原認識ドメインは、CD20、CD22、CD33、CD123、CD267、CD269、CD38またはCD1を含む、請求項１２に記載の方法。
- 第1の抗原認識ドメインはCD19を含み、第2の抗原認識ドメインはCD123を含む、請求項１２に記載の方法。
- 第1の抗原認識ドメインはCD33を含み、第2の抗原認識ドメインはCD123を含む、請求項１２に記載の方法。
- 第1の抗原認識ドメインはBCMAを含み、第2の抗原認識ドメインは、CS1、CD19、CD38、CD138、またはCS1を含む、請求項１２に記載の方法。
- 操作された細胞は、T細胞、CD4 T細胞、CD8 T細胞、ナチュラルキラー細胞、NKT細胞またはNK-92細胞である、請求項１２に記載の方法。
- 第1の共刺激ドメインはCD28を含み、第2の共刺激ドメインは4-1BBを含む、請求項１２に記載の方法。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021167360A JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2023053851A JP7502515B2 (ja) | 2015-06-25 | 2023-03-29 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562184321P | 2015-06-25 | 2015-06-25 | |
| US62/184,321 | 2015-06-25 | ||
| US201562235840P | 2015-10-01 | 2015-10-01 | |
| US62/235,840 | 2015-10-01 | ||
| US201562244435P | 2015-10-21 | 2015-10-21 | |
| US62/244,435 | 2015-10-21 | ||
| PCT/US2016/039306 WO2016210293A1 (en) | 2015-06-25 | 2016-06-24 | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021167360A Division JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518974A JP2018518974A (ja) | 2018-07-19 |
| JP2018518974A5 true JP2018518974A5 (ja) | 2019-07-18 |
| JP6961497B2 JP6961497B2 (ja) | 2021-11-05 |
Family
ID=57586695
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567178A Active JP6961497B2 (ja) | 2015-06-25 | 2016-06-24 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2021167360A Active JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2023053851A Active JP7502515B2 (ja) | 2015-06-25 | 2023-03-29 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021167360A Active JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2023053851A Active JP7502515B2 (ja) | 2015-06-25 | 2023-03-29 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11655452B2 (ja) |
| EP (1) | EP3313872A4 (ja) |
| JP (3) | JP6961497B2 (ja) |
| KR (1) | KR20180021137A (ja) |
| CN (2) | CN115058395A (ja) |
| AU (3) | AU2016283102B2 (ja) |
| CA (1) | CA2990177A1 (ja) |
| IL (2) | IL256410B (ja) |
| SG (1) | SG10201913682QA (ja) |
| TW (1) | TWI833684B (ja) |
| WO (1) | WO2016210293A1 (ja) |
Families Citing this family (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| CN106459914B (zh) | 2014-05-15 | 2020-11-06 | 新加坡国立大学 | 经修饰的自然杀伤细胞及其用途 |
| HRP20240357T1 (hr) | 2014-12-24 | 2024-06-07 | Autolus Limited | Stanica |
| WO2017222593A1 (en) | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| AU2016283102B2 (en) * | 2015-06-25 | 2021-03-11 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| US11293021B1 (en) | 2016-06-23 | 2022-04-05 | Inscripta, Inc. | Automated cell processing methods, modules, instruments, and systems |
| US11078481B1 (en) | 2016-08-03 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for screening for cancer targets |
| CN117298260A (zh) * | 2016-09-02 | 2023-12-29 | 莱蒂恩技术公司 | 用DuoCAR治疗癌症的组合物和方法 |
| CA3042613A1 (en) * | 2016-11-11 | 2018-05-17 | Autolus Limited | Chimeric antigen receptor |
| AU2017363311A1 (en) * | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CA3045386A1 (en) | 2016-12-09 | 2018-06-14 | Onkimmune Limited | Engineered natural killer cells and uses thereof |
| JP7033601B2 (ja) | 2017-01-05 | 2022-03-10 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | 抗コチニンキメラ抗原受容体を発現するナチュラルキラー細胞 |
| WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| US20190381101A1 (en) * | 2017-02-01 | 2019-12-19 | Nant Holdings Ip, Llc | Calreticulin-mediated cancer treatment |
| IL269203B1 (en) | 2017-03-13 | 2024-05-01 | Poseida Therapeutics Inc | Preparations and methods for the selective elimination and replacement of hematopoietic stem cells |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| CN110494557A (zh) | 2017-03-27 | 2019-11-22 | 新加坡国立大学 | 用于离体扩增和活化自然杀伤细胞的刺激细胞系 |
| US20200048618A1 (en) * | 2017-04-18 | 2020-02-13 | Autolus Limited | Cell |
| WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| CA3062433A1 (en) | 2017-05-15 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
| EP3635099A4 (en) * | 2017-06-07 | 2021-02-24 | The General Hospital Corporation | T-CELLS WITH EXPRESSION OF A CHIMERIC ANTIGEN RECEPTOR |
| MX2019014960A (es) | 2017-06-12 | 2020-08-06 | Obsidian Therapeutics Inc | Composiciones de fosfodiesterasa de tipo 5 (pde5) y métodos de inmunoterapia. |
| SG11202000555UA (en) * | 2017-06-21 | 2020-02-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| WO2019006464A1 (en) * | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | COMPOSITIONS AND METHODS OF ADOPTIVE CELLULAR THERAPY AGAINST CANCER |
| HRP20220615T1 (hr) | 2017-06-30 | 2022-06-24 | Inscripta, Inc. | Postupci, moduli, instrumenti i sustavi za automatiziranu obradu stanica |
| US11471490B2 (en) * | 2017-07-03 | 2022-10-18 | Torque Therapeutics, Inc. | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof |
| WO2019018525A1 (en) * | 2017-07-20 | 2019-01-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CHIMERIC ANTIGENIC RECEPTORS BINDING TO CD123 |
| CA3075630A1 (en) * | 2017-09-29 | 2019-04-04 | Nantcell, Inc. | Cd1d and tcr-nkt cells |
| SG11202003258QA (en) * | 2017-10-12 | 2020-05-28 | Icell Gene Therapeutics Llc | Compound chimeric antigen receptor (ccar) targeting multiple antigens, compositions and methods of use thereof |
| EP3697436A1 (en) | 2017-10-18 | 2020-08-26 | Novartis AG | Compositions and methods for selective protein degradation |
| US20210187024A1 (en) * | 2017-11-01 | 2021-06-24 | Nantkwest, Inc. | NK-92 Cells to Stimulate Anti-Cancer Vaccine |
| BR112020009336A2 (pt) | 2017-11-15 | 2020-10-27 | Novartis Ag | receptor quimérico de antígenos de alvejamento de bcma, receptor quimérico de antígenos de alvejamento de cd19 e terapias de combinação |
| BR112020010579A2 (pt) | 2017-11-30 | 2020-11-10 | Novartis Ag | receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo |
| WO2019111249A1 (en) | 2017-12-05 | 2019-06-13 | The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof |
| CN112218651A (zh) | 2018-01-08 | 2021-01-12 | 诺华公司 | 用于与嵌合抗原受体疗法组合的免疫增强rna |
| AU2019215031A1 (en) | 2018-01-31 | 2020-08-20 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| CN112004832A (zh) * | 2018-02-23 | 2020-11-27 | H·李·莫菲特癌症中心研究所公司 | 结合cd83的嵌合抗原受体 |
| KR20200130709A (ko) | 2018-03-06 | 2020-11-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 전립선-특이 막 항원 car 및 이의 사용 방법 |
| WO2019199793A1 (en) * | 2018-04-09 | 2019-10-17 | Mayo Foundation For Medical Education And Research | Methods and materials for treating graft-versus-host disease |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
| US10557216B2 (en) | 2018-04-24 | 2020-02-11 | Inscripta, Inc. | Automated instrumentation for production of T-cell receptor peptide libraries |
| EP3561053A1 (en) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| CA3098014A1 (en) * | 2018-04-27 | 2019-10-31 | Crispr Therapeutics Ag | Anti-bcma car-t-cells for plasma cell depletion |
| MX2020012927A (es) * | 2018-06-01 | 2021-03-25 | Univ Southern California | Diversos dominios de enlace de antigenos, nuevas plataformas y otras mejoras para terapia celular. |
| CN110577605A (zh) * | 2018-06-11 | 2019-12-17 | 浙江启新生物技术有限公司 | 一种靶向多发性骨髓瘤多种抗原的嵌合抗原受体t（car-t）细胞的构建方法及其应用 |
| CN110305847B (zh) * | 2018-07-27 | 2021-05-18 | 赛诺生（深圳）基因产业发展有限公司 | 一种用于治疗肿瘤的基因工程细胞 |
| CA3107119A1 (en) * | 2018-07-31 | 2020-02-06 | Washington University | Use of interleukin-7 and chimeric antigen receptor (car)-bearing immune effector cells for treating tumor |
| KR102653878B1 (ko) | 2018-08-01 | 2024-04-01 | 난트퀘스트, 인크. | 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 (a quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies) |
| US20210308171A1 (en) * | 2018-08-07 | 2021-10-07 | The Broad Institute, Inc. | Methods for combinatorial screening and use of therapeutic targets thereof |
| GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
| IL292273B2 (en) | 2018-08-14 | 2023-10-01 | Inscripta Inc | Devices, modules and methods for improved detection of edited sequences in living cells |
| CN109306016B (zh) * | 2018-08-15 | 2021-10-22 | 华东师范大学 | 共表达细胞因子il-7的nkg2d-car-t细胞及其用途 |
| US20220348682A1 (en) | 2018-08-30 | 2022-11-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| TW202030323A (zh) | 2018-08-31 | 2020-08-16 | 瑞士商諾華公司 | 製備表現嵌合抗原受體的細胞之方法 |
| US20210363245A1 (en) * | 2018-09-17 | 2021-11-25 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses |
| WO2020061796A1 (en) * | 2018-09-26 | 2020-04-02 | Hrain Biotechnology Co., Ltd. | Bcma-and-cd19-targeting chimeric antigen receptor and uses thereof |
| EP3864142A4 (en) * | 2018-10-12 | 2023-07-19 | iCell Gene Therapeutics LLC | CHIMERIC ANTIGEN RECEPTOR (CARS) COMPOSITIONS AND METHODS OF USE THEREOF |
| CA3116138A1 (en) * | 2018-10-17 | 2020-04-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11214781B2 (en) | 2018-10-22 | 2022-01-04 | Inscripta, Inc. | Engineered enzyme |
| US11077143B2 (en) * | 2018-10-31 | 2021-08-03 | Nantkwest Inc. | Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells |
| KR20230150399A (ko) * | 2018-10-31 | 2023-10-30 | 난트퀘스트, 인크. | Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거 |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| WO2020112563A1 (en) * | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| US11793834B2 (en) | 2018-12-12 | 2023-10-24 | Kite Pharma, Inc. | Chimeric antigen and T cell receptors and methods of use |
| JP2022524178A (ja) * | 2019-01-07 | 2022-04-28 | セルリス パルティシパソエス リミターダ | タンデム受容体ｃａｒにおける二重特異性と腫瘍マイクロ環境を変調する方法 |
| CA3130489A1 (en) * | 2019-02-18 | 2020-08-27 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| KR20210134339A (ko) | 2019-02-25 | 2021-11-09 | 노파르티스 아게 | 바이러스 전달을 위한 메조다공성 실리카 입자 조성물 |
| SG11202109057XA (en) | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US12018061B2 (en) * | 2019-03-08 | 2024-06-25 | St Phi Therapeutics Co., Ltd. | Chimeric endocytic receptors and method of use thereof |
| WO2020190902A1 (en) * | 2019-03-19 | 2020-09-24 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptors with enhanced tumor infiltration |
| WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
| CN113631713A (zh) | 2019-03-25 | 2021-11-09 | 因思科瑞普特公司 | 酵母中的同时多重基因组编辑 |
| US11001831B2 (en) | 2019-03-25 | 2021-05-11 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| EP3953455A1 (en) | 2019-04-12 | 2022-02-16 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| CN114007626A (zh) * | 2019-04-26 | 2022-02-01 | 艾丽塔生物治疗剂公司 | 用于治疗癌症的组合物和方法 |
| CN114007642A (zh) | 2019-04-30 | 2022-02-01 | 森迪生物科学公司 | 嵌合受体及其使用方法 |
| CA3139122C (en) | 2019-06-06 | 2023-04-25 | Inscripta, Inc. | Curing for recursive nucleic acid-guided cell editing |
| CN110452294B (zh) * | 2019-08-06 | 2020-08-07 | 复旦大学 | 五种铰链区及其嵌合抗原受体和免疫细胞 |
| AU2020334317A1 (en) | 2019-08-16 | 2022-04-07 | Janssen Biotech, Inc. | Therapeutic immune cells with improved function and methods for making the same |
| CN112442509A (zh) * | 2019-08-29 | 2021-03-05 | 爱博赛特生物治疗公司 | Cd19-cd20双特异性和双通道car-t及其使用方法 |
| CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| WO2021102059A1 (en) | 2019-11-19 | 2021-05-27 | Inscripta, Inc. | Methods for increasing observed editing in bacteria |
| IL292924A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors cd19 and cd22 and their uses |
| EP4065158A2 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
| KR20220137882A (ko) * | 2019-12-05 | 2022-10-12 | 바이셀릭스, 인크. | 보편적 세포 요법을 위한 면역 회피 기작의 조절제 |
| KR20220118498A (ko) | 2019-12-18 | 2022-08-25 | 인스크립타 인코포레이티드 | 핵산-가이드된 뉴클레아제 편집된 세포의 생체 내 검출을 위한 캐스케이드/dcas3 상보 검정 |
| WO2021146147A1 (en) * | 2020-01-13 | 2021-07-22 | Nkarta, Inc. | Bcma-directed cellular immunotherapy compositions and methods |
| AU2021213705A1 (en) | 2020-01-27 | 2022-06-16 | Inscripta, Inc. | Electroporation modules and instrumentation |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| US20210238535A1 (en) * | 2020-02-02 | 2021-08-05 | Inscripta, Inc. | Automated production of car-expressing cells |
| JP2023512657A (ja) * | 2020-02-05 | 2023-03-28 | ワシントン・ユニバーシティ | Ｉｌ－７タンパク質とｃａｒ保有免疫細胞の組み合わせで固形腫瘍を治療する方法 |
| EP4110377A2 (en) | 2020-02-27 | 2023-01-04 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| BR112022017148A2 (pt) | 2020-02-27 | 2022-11-08 | Novartis Ag | Métodos para produzir células que expressam receptor de antígeno quimérico |
| CA3170369A1 (en) | 2020-03-05 | 2022-04-14 | Michal Shahar | Methods and compositions for treating cancer with immune cells |
| US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
| JP2023525032A (ja) | 2020-05-08 | 2023-06-14 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｔ細胞阻害タンパク質を伴うおよび伴わない、ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 |
| US20230227525A1 (en) * | 2020-05-08 | 2023-07-20 | Smt Bio Co., Ltd. | Chimeric antigen receptor for treatment of cancer |
| US11787841B2 (en) | 2020-05-19 | 2023-10-17 | Inscripta, Inc. | Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli |
| EP4157863A2 (en) * | 2020-05-29 | 2023-04-05 | iCell Gene Therapeutics, LLC | Engineered immune cells, compositions and methods thereof |
| AU2021288224A1 (en) | 2020-06-11 | 2023-01-05 | Novartis Ag | ZBTB32 inhibitors and uses thereof |
| CA3188978A1 (en) | 2020-08-21 | 2022-02-24 | Sandeep Tharian Koshy | Compositions and methods for in vivo generation of car expressing cells |
| TW202216990A (zh) * | 2020-09-08 | 2022-05-01 | 中國大陸商亘喜生物科技（上海）有限公司 | 用於ｔ細胞工程化的組合物和方法 |
| WO2022060749A1 (en) | 2020-09-15 | 2022-03-24 | Inscripta, Inc. | Crispr editing to embed nucleic acid landing pads into genomes of live cells |
| WO2022076256A1 (en) * | 2020-10-05 | 2022-04-14 | Icell Gene Therapeutics Llc | Engineered immune cells for immunotherapy using endoplasmic retention techniques |
| US11512297B2 (en) | 2020-11-09 | 2022-11-29 | Inscripta, Inc. | Affinity tag for recombination protein recruitment |
| CN116648457A (zh) * | 2020-12-31 | 2023-08-25 | 亘喜生物科技（上海）有限公司 | 膜融合蛋白及其在免疫细胞中的应用 |
| EP4271802A1 (en) | 2021-01-04 | 2023-11-08 | Inscripta, Inc. | Mad nucleases |
| WO2022150269A1 (en) | 2021-01-07 | 2022-07-14 | Inscripta, Inc. | Mad nucleases |
| CN112778427B (zh) * | 2021-01-29 | 2022-03-15 | 武汉思安医疗技术有限公司 | 双特异性cs1-bcma car-t细胞及其应用 |
| US11884924B2 (en) | 2021-02-16 | 2024-01-30 | Inscripta, Inc. | Dual strand nucleic acid-guided nickase editing |
| CN112698037B (zh) * | 2021-03-25 | 2021-06-25 | 北京积水潭医院 | 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用 |
| TW202309294A (zh) | 2021-04-27 | 2023-03-01 | 瑞士商諾華公司 | 病毒載體生產系統 |
| EP4388000A1 (en) | 2021-08-20 | 2024-06-26 | Novartis AG | Methods of making chimeric antigen receptor?expressing cells |
| CN114835820B (zh) * | 2022-04-14 | 2023-01-06 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 用于基因改造的多能干细胞及、自然杀伤细胞的嵌合型Fc受体 |
| CN115232217B (zh) * | 2022-07-04 | 2023-06-06 | 深圳市先康达生命科学有限公司 | 一种SynNotch结构及其应用 |
| GB202209920D0 (en) * | 2022-07-06 | 2022-08-17 | Autolus Ltd | Cell |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
| KR20240072334A (ko) * | 2022-11-11 | 2024-05-24 | 주식회사 유씨아이테라퓨틱스 | 유전자 조작된 세포 및 이의 용도 |
| KR20240081499A (ko) * | 2022-11-11 | 2024-06-10 | 주식회사 유씨아이테라퓨틱스 | 유전자 조작된 세포 및 이의 용도 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US20030147865A1 (en) | 2002-02-07 | 2003-08-07 | Benoit Salomon | Cell therapy using immunoregulatory T-cells |
| US20080254027A1 (en) | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
| CA2497628A1 (en) | 2002-09-05 | 2004-03-18 | Medimmune, Inc. | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| WO2005108415A2 (en) | 2004-04-30 | 2005-11-17 | Biogen Idec Ma Inc. | Membrane associated molecules |
| US20050277587A1 (en) | 2004-06-10 | 2005-12-15 | Academia Sinica | CD7 as biomarker and therapeutic target for psoriasis |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| CA2636424A1 (en) | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy |
| MX2008015866A (es) | 2006-06-12 | 2009-01-14 | Centocor Inc | Metodo para detectar actividad de interleucina-16 y modulacion de la actividad de interleucina-16 con base en niveles proxi de celulas t normales expresadas y secretadas, reguladas sobre activacion. |
| US20080254512A1 (en) | 2006-11-02 | 2008-10-16 | Capon Daniel J | Hybrid immunoglobulins with moving parts |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| WO2010085660A2 (en) | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| WO2010132697A2 (en) | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Methods and compositions for treatment |
| CA2761885A1 (en) | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Methods and compositions for treating lupus |
| EP2325322A1 (en) | 2009-11-23 | 2011-05-25 | 4-Antibody AG | Retroviral vector particles and methods for their generation and use |
| KR20230133410A (ko) | 2010-12-09 | 2023-09-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
| EP3693017A1 (en) | 2010-12-14 | 2020-08-12 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| CN106692193B (zh) | 2011-04-06 | 2021-01-05 | 桑比欧公司 | 用于调节外周免疫功能的方法和组合物 |
| RU2605390C2 (ru) | 2011-08-23 | 2016-12-20 | Рош Гликарт Аг | Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения |
| AU2013221672B2 (en) * | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| US10040846B2 (en) | 2012-02-22 | 2018-08-07 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| WO2014011987A1 (en) * | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating car t cells |
| CN104853766A (zh) | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| WO2014055657A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| CN107988165A (zh) * | 2013-02-06 | 2018-05-04 | 人类起源公司 | 具有改进特异性的修饰的t淋巴细胞 |
| PL2956175T3 (pl) * | 2013-02-15 | 2018-05-30 | The Regents Of The University Of California | Chimeryczny receptor antygenowy i sposoby jego zastosowania |
| EP3744736A1 (en) * | 2013-02-20 | 2020-12-02 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| EP2970426B1 (en) * | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| LT3546572T (lt) | 2013-05-13 | 2024-05-27 | Cellectis | Cd19 specifinis chimerinis antigeno receptorius ir jo panaudojimas |
| US9629877B2 (en) * | 2013-05-14 | 2017-04-25 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (CAR) T-cells |
| PT3030262T (pt) | 2013-08-08 | 2019-12-11 | Inst Gustave Roussy Igr | Composição farmacêutica de associação |
| KR20160079854A (ko) | 2013-10-31 | 2016-07-06 | 프레드 헛친슨 켄서 리서치 센터 | 변형된 조혈 줄기/선조 및 비-t 효과기 세포 및 이의 용도 |
| US9493563B2 (en) | 2013-11-04 | 2016-11-15 | Glenmark Pharmaceuticals S.A. | Production of T cell retargeting hetero-dimeric immunoglobulins |
| JP6538684B2 (ja) | 2013-11-21 | 2019-07-03 | ユーシーエル ビジネス ピーエルシー | 細胞 |
| EP3097117B1 (en) | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| EP3102236A4 (en) | 2014-02-05 | 2017-08-30 | The University of Chicago | Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants |
| HUE041497T2 (hu) | 2014-02-14 | 2019-05-28 | Cellectis | Immunsejteken és patológiás sejteken egyaránt jelen lévõ antigént célzó génmódosított sejtek immunterápia célra |
| EP3943507A1 (en) | 2014-04-10 | 2022-01-26 | Seattle Children's Hospital, dba Seattle Children's Research Institute | Drug related transgene expression |
| CN113604491A (zh) | 2014-05-02 | 2021-11-05 | 宾夕法尼亚大学董事会 | 嵌合自身抗体受体t细胞的组合物和方法 |
| KR20200000495A (ko) | 2014-05-14 | 2020-01-02 | 카르스젠 테라퓨틱스 리미티드 | 키메라 항원 수용체 단백질을 코딩하는 핵산 및 키메라 항원 수용체 단백질을 발현하는 t 림프구 |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| MY189028A (en) * | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| EP3186284B1 (en) | 2014-08-28 | 2022-04-06 | BioAtla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| MX2017004603A (es) * | 2014-10-07 | 2017-06-30 | Cellectis | Metodo para modular actividad de celulas inmunes inducidas por car. |
| HRP20240357T1 (hr) | 2014-12-24 | 2024-06-07 | Autolus Limited | Stanica |
| AU2016225012B2 (en) * | 2015-02-27 | 2020-09-03 | Kevin Chen | Chimeric antigen receptors (CARS) targeting hematologic malignancies, compositions and methods of use thereof |
| SI3280729T1 (sl) * | 2015-04-08 | 2022-09-30 | Novartis Ag | Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR) |
| WO2017222593A1 (en) * | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| US20220241327A1 (en) * | 2015-06-25 | 2022-08-04 | Icell Gene Therapeutics Llc | Chimeric Antigen Receptor (CAR) Targeting Multiple Antigens, Compositions and Methods of Use Thereof |
| US11173179B2 (en) * | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| AU2016283102B2 (en) * | 2015-06-25 | 2021-03-11 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| US20190135894A1 (en) * | 2015-06-25 | 2019-05-09 | iCell Gene Therapeuticics LLC | COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| CN105087495B (zh) * | 2015-08-21 | 2016-04-27 | 深圳市茵冠生物科技有限公司 | 双嵌合抗原受体修饰的t淋巴细胞及其制备方法 |
| GB201518817D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
| WO2017112877A1 (en) * | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| SG11202000555UA (en) * | 2017-06-21 | 2020-02-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| SG11202003258QA (en) * | 2017-10-12 | 2020-05-28 | Icell Gene Therapeutics Llc | Compound chimeric antigen receptor (ccar) targeting multiple antigens, compositions and methods of use thereof |
| BR112020010579A2 (pt) * | 2017-11-30 | 2020-11-10 | Novartis Ag | receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo |
-
2016
- 2016-06-24 AU AU2016283102A patent/AU2016283102B2/en active Active
- 2016-06-24 KR KR1020187002389A patent/KR20180021137A/ko not_active Application Discontinuation
- 2016-06-24 US US15/739,596 patent/US11655452B2/en active Active
- 2016-06-24 SG SG10201913682QA patent/SG10201913682QA/en unknown
- 2016-06-24 EP EP16815399.7A patent/EP3313872A4/en active Pending
- 2016-06-24 CA CA2990177A patent/CA2990177A1/en active Pending
- 2016-06-24 CN CN202210523997.3A patent/CN115058395A/zh active Pending
- 2016-06-24 WO PCT/US2016/039306 patent/WO2016210293A1/en active Application Filing
- 2016-06-24 TW TW105120100A patent/TWI833684B/zh active
- 2016-06-24 CN CN201680036459.4A patent/CN107849112B/zh active Active
- 2016-06-24 JP JP2017567178A patent/JP6961497B2/ja active Active
-
2017
- 2017-12-19 IL IL256410A patent/IL256410B/en unknown
-
2021
- 2021-05-28 AU AU2021203481A patent/AU2021203481B2/en active Active
- 2021-10-12 JP JP2021167360A patent/JP7254870B2/ja active Active
- 2021-10-31 IL IL287718A patent/IL287718A/en unknown
-
2023
- 2023-03-29 JP JP2023053851A patent/JP7502515B2/ja active Active
- 2023-09-22 AU AU2023233207A patent/AU2023233207A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518974A5 (ja) | ||
| JP2019522973A5 (ja) | ||
| Klein et al. | Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines | |
| Jacoby et al. | CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity | |
| Lorenzo-Herrero et al. | NK cell-based immunotherapy in cancer metastasis | |
| Stoiber et al. | Limitations in the design of chimeric antigen receptors for cancer therapy | |
| Sadelain | CAR therapy: the CD19 paradigm | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| Verdon et al. | Cellular and molecular mechanisms of CD8+ T cell differentiation, dysfunction and exhaustion | |
| Waldmann | The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy | |
| Birkholz et al. | Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer | |
| JP2020074776A5 (ja) | ||
| Leisegang et al. | T-Cell Receptor Gene–Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy | |
| Ghasemi et al. | Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy | |
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| Firor et al. | From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy | |
| JP2017513470A5 (ja) | ||
| Ding et al. | Fusion proteins of NKG2D/NKG2DL in cancer immunotherapy | |
| RU2018118652A (ru) | Химерные конструкции антитело/т-клеточный рецептор и их применения | |
| JP2020517259A5 (ja) | ||
| RU2016143388A (ru) | Экспрессия трансгенов, регулируемая лекарственным средством | |
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| RU2017121115A (ru) | Генетически модифицированные гамма дельта т-клетки | |
| JP2017506513A5 (ja) | ||
| JP2019528769A5 (ja) |